$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

$ptn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000165495424006292 Filed on May 15, 2024

Income Statement

Concept	2024 Q2	2024 Q1
Revenue	$350.0K	$0.00
YoY Change	-80.11%	-100.0%
Cost Of Revenue	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Gross Profit	$350.0K	$0.00
YoY Change	-78.92%	-100.0%
Gross Profit Margin	100.0%
Selling, General & Admin	$4.004M	$2.033M
YoY Change	-21.03%	-42.52%
% of Gross Profit	1143.94%
Research & Development	$4.672M	$7.160M
YoY Change	-36.95%	48.22%
% of Gross Profit	1334.82%
Depreciation & Amortization	$81.96K	$85.06K
YoY Change	2.45%	9.22%
% of Gross Profit	23.42%
Operating Expenses	$8.676M	$9.218M
YoY Change	-30.48%	8.49%
Operating Profit	-$8.326M	-$9.218M
YoY Change	-23.05%	26.26%
Interest Expense	$91.64K	$1.254K
YoY Change	-8.36%	-63.48%
% of Operating Profit
Other Income/Expense, Net	$0.00	$0.00
YoY Change		-100.0%
Pretax Income	-$8.250M	-$8.410M
YoY Change	-22.97%	17.66%
Income Tax	$0.00	$0.00
% Of Pretax Income
Net Earnings	-$8.250M	-$8.436M
YoY Change	-22.97%	18.02%
Net Earnings / Revenue	-2357.27%
Basic Earnings Per Share
Diluted Earnings Per Share	-$0.49	-$0.53
COMMON SHARES
Basic Shares Outstanding	16.14M shares	16.14M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2024 Q2	2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$9.527M	$10.01M
YoY Change	-13.39%	-48.99%
Cash & Equivalents	$9.527M	$9.224M
Short-Term Investments	$0.00	$0.00
Other Short-Term Assets	$242.3K	$254.6K
YoY Change	-87.25%	-88.82%
Inventory	$0.00	$0.00
Prepaid Expenses
Receivables	$0.00	$0.00
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$9.770M	$10.27M
YoY Change	-40.14%	-57.64%
LONG-TERM ASSETS
Property, Plant & Equipment	$388.4K	$465.4K
YoY Change	-43.3%	-34.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$56.92K	$56.92K
YoY Change	0.0%	0.0%
Total Long-Term Assets	$972.6K	$1.138M
YoY Change	-39.89%	-16.96%
TOTAL ASSETS
Total Short-Term Assets	$9.770M	$10.27M
Total Long-Term Assets	$972.6K	$1.138M
Total Assets	$10.74M	$11.41M
YoY Change	-40.12%	-55.46%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.102M	$3.443M
YoY Change	-4.68%	23.58%
Accrued Expenses	$4.185M	$2.365M
YoY Change	-35.72%	-57.28%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$46.01K	$73.14K
YoY Change	-53.99%	-30.34%
Total Short-Term Liabilities	$9.658M	$8.533M
YoY Change	-36.18%	-28.0%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change		-100.0%
Other Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
Total Long-Term Liabilities	$0.00	$0.00
YoY Change	-100.0%	-100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.658M	$8.533M
Total Long-Term Liabilities	$0.00	$0.00
Total Liabilities	$10.85M	$9.827M
YoY Change	-39.04%	-38.64%
SHAREHOLDERS EQUITY
Retained Earnings	-$441.8M	-$433.5M
YoY Change	6.31%	7.09%
Common Stock	$179.3K	$161.4K
YoY Change	53.79%	44.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$111.5K	$1.579M
YoY Change
Total Liabilities & Shareholders Equity	$10.74M	$11.41M
YoY Change	-40.12%	-55.46%

Cashflow Statement

Concept	2024 Q2	2024 Q1
OPERATING ACTIVITIES
Net Income	-$8.250M	-$8.436M
YoY Change	-22.97%	18.02%
Depreciation, Depletion And Amortization	$81.96K	$85.06K
YoY Change	2.45%	9.22%
Cash From Operating Activities	-$6.472M	-$8.607M
YoY Change	-32.65%	511.15%
INVESTING ACTIVITIES
Capital Expenditures	$4.910K	$0.00
YoY Change	-90.18%	-100.0%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$4.920K	$0.00
YoY Change	-99.84%	-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	5.991M	9.136M
YoY Change	493.14%	-36181.16%
NET CHANGE
Cash From Operating Activities	-6.472M	-8.607M
Cash From Investing Activities	-4.920K	0.000
Cash From Financing Activities	5.991M	9.136M
Net Change In Cash	-486.7K	528.8K
YoY Change	-95.82%	-134.11%
FREE CASH FLOW
Cash From Operating Activities	-$6.472M	-$8.607M
Capital Expenditures	$4.910K	$0.00
Free Cash Flow	-$6.477M	-$8.607M
YoY Change	-32.95%	464.32%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	8496938	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-9218298	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1254	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3434	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0000911216
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--06-30
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11656714	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16136640	shares
CY2024Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	21485683	usd
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	279700	shares
CY2017Q3	us-gaap	Officers Compensation OfficersCompensation	417500	usd
CY2017Q3	ptn	Tax Expense TaxExpense	82500	usd
CY2024Q1	ptn	Equity Gross Proceeds Shares EquityGrossProceedsShares	0	shares
	ptn	Equity Fees Shares EquityFeesShares	0	shares
CY2024Q1	ptn	Equity Fees Shares EquityFeesShares	0	shares
CY2024Q1	ptn	Equity Expenses Shares EquityExpensesShares	0	shares
	ptn	Equity Expenses Shares EquityExpensesShares	0	shares
CY2024Q1	ptn	Equity Net Proceeds Shares EquityNetProceedsShares	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	0	shares
CY2022Q4	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	121584	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	382541	usd
	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	1033491	shares
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-15543
	dei	Entity Registrant Name EntityRegistrantName	PALATIN TECHNOLOGIES, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	95-4078884
	dei	Entity Address Address Line1 EntityAddressAddressLine1	4B Cedar Brook Drive
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cranbury
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NJ
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	08512
	dei	City Area Code CityAreaCode	609
	dei	Local Phone Number LocalPhoneNumber	495‑2200
	dei	Security12b Title Security12bTitle	Common Stock, par value $0.01 per share
	dei	Trading Symbol TradingSymbol	PTN
	dei	Security Exchange Name SecurityExchangeName	NYSE
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16136640	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11656714	shares
CY2024Q1	us-gaap	Revenues Revenues	0	usd
CY2023Q1	us-gaap	Revenues Revenues	1195675	usd
	us-gaap	Revenues Revenues	4140090	usd
	us-gaap	Revenues Revenues	3091745	usd
CY2024Q1	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	129235	usd
CY2024Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7159686	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4830327	usd
CY2024Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2033410	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	3537376	usd
CY2024Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	25202	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	0	usd
CY2024Q1	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
CY2023Q1	ptn	Gain Loss On Purchase Commitment GainLossOnPurchaseCommitment	0	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	9218298	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-7301263	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	139273	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	234044	usd
CY2024Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	215600	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-77266	usd
CY2024Q1	us-gaap	Other Expenses OtherExpenses	0	usd
CY2023Q1	us-gaap	Other Expenses OtherExpenses	0	usd
CY2024Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	429029	usd
CY2023Q1	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	-1521413	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	782648	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1368069	usd
CY2024Q1	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	-8435650	usd
CY2023Q1	us-gaap	Income Loss From Subsidiaries Before Tax IncomeLossFromSubsidiariesBeforeTax	-8669332	usd
CY2024Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8435650	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8669332	usd
CY2024Q1	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.53
CY2023Q1	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-0.76
	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-1.53
	ptn	Earning Per Share Basic And Diluted EarningPerShareBasicAndDiluted	-1.34
CY2024Q1	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	15792421	shares
CY2023Q1	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	11432380	shares
	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	14013848	shares
	ptn	Weighted Average Number Of Common Shares Outstanding Used In Computing Basic And Diluted WeightedAverageNumberOfCommonSharesOutstandingUsedInComputingBasicAndDiluted	10613830	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-11384426	usd
CY2024Q1	ptn	Stock Based Compensation Amount StockBasedCompensationAmount	390195	usd
CY2024Q1	ptn	Sale Of Common Stock Net Of Costs Amount SaleOfCommonStockNetOfCostsAmount	9162513	usd
CY2024Q1	ptn	Conversion Of Liability Classified Warrants ConversionOfLiabilityClassifiedWarrants	11423203	usd
CY2024Q1	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	423100	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8435650	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1578935	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-1979871	usd
	ptn	Stock Based Compensation Amount StockBasedCompensationAmount	1330502	usd
	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	-56401	usd
	ptn	Sale Of Common Stock Net Of Costs Amount SaleOfCommonStockNetOfCostsAmount	9693882	usd
	ptn	Conversion Of Liability Classified Warrants ConversionOfLiabilityClassifiedWarrants	11423203	usd
	ptn	Conversion Of Liability Classified Warrants Upon Warrant Exercise Amount ConversionOfLiabilityClassifiedWarrantsUponWarrantExerciseAmount	2389903	usd
	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	263400	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21485683	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	1578935	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	11531386	usd
CY2023Q1	ptn	Stock Based Compensation Amount StockBasedCompensationAmount	396757	usd
CY2023Q1	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	0	usd
CY2023Q1	ptn	Redemption Of Convertible Series B Series C Preferred Stock RedemptionOfConvertibleSeriesBSeriesCPreferredStock	0	usd
CY2023Q1	ptn	Conversion Of Liability Classified Warrants ConversionOfLiabilityClassifiedWarrants	3324653	usd
CY2023Q1	ptn	Warrant Exercises Amount WarrantExercisesAmount	78	usd
CY2023Q1	ptn	Sale Of Common Stock And Warrants Net Of Costs SaleOfCommonStockAndWarrantsNetOfCosts	0	usd
CY2023Q1	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	0	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-8669332	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6583542	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	16267875	usd
	ptn	Stock Based Compensation Amount StockBasedCompensationAmount	1452338	usd
	ptn	Withholding Taxes Related To Restricted Stock Units Amount WithholdingTaxesRelatedToRestrictedStockUnitsAmount	-146062	usd
	ptn	Redemption Of Convertible Series B Series C Preferred Stock Amount RedemptionOfConvertibleSeriesBSeriesCPreferredStockAmount	0	usd
	ptn	Sale Of Common Stock And Warrants Net Of Costs Amount SaleOfCommonStockAndWarrantsNetOfCostsAmount	165354	usd
	ptn	Conversion Of Liability Classified Warrants ConversionOfLiabilityClassifiedWarrants	3324653	usd
	ptn	Warrant Excercises Amount WarrantExcercisesAmount	78	usd
	ptn	Reverse Stock Split Fractional Shares Amount ReverseStockSplitFractionalSharesAmount	0	usd
	ptn	Reclassification Of Contingently Redeemable Warrants ReclassificationOfContingentlyRedeemableWarrants	-263400	usd
	us-gaap	Net Income Loss NetIncomeLoss	-14217294	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6583542	usd
	ptn	Unrealized Foreign Currency Transaction Gain UnrealizedForeignCurrencyTransactionGain	-68653	usd
	ptn	Unrealized Foreign Currency Transaction Gain UnrealizedForeignCurrencyTransactionGain	352121	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-433516120	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-8435650	usd
	us-gaap	Net Income Loss NetIncomeLoss	-21485683	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	8532782	usd
	ptn	Description Of Sales Based Payments DescriptionOfSalesBasedPayments	The Company may receive contingent, sales-based milestone payments of up to $159,000,000 on sales of Vyleesi by Cosette and its licensees
CY2024Q1	us-gaap	Servicing Liability At Fair Value Other Changes In Fair Value ServicingLiabilityAtFairValueOtherChangesInFairValue	-1521413	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Use of Estimates</em> – The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><em>Credit Risk</em> – Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents, and accounts receivable. Total cash and cash equivalent balances have exceeded balances insured by the Federal Depository Insurance Company. Product revenues and related accounts receivable are generated primarily from one specialty pharmacy. </p>
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8520332	shares
CY2024Q1	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	279700	shares
	us-gaap	Accounts Receivable Purchase AccountsReceivablePurchase	171000000	usd
	us-gaap	Supplemental Deferred Purchase Price SupplementalDeferredPurchasePrice	9500000	usd
	us-gaap	Payments For Purchase Of Other Assets1 PaymentsForPurchaseOfOtherAssets1	2500000	usd
	ptn	Payments To Sales Based Milestone Payments PaymentsToSalesBasedMilestonePayments	159000000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	7798280	usd
	us-gaap	Long Term Purchase Commitment Amount LongTermPurchaseCommitmentAmount	1027322	usd
CY2017Q3	us-gaap	Increase Decrease In Deferred Revenue And Customer Advances And Deposits IncreaseDecreaseInDeferredRevenueAndCustomerAdvancesAndDeposits	4500000	usd
CY2017Q3	us-gaap	Payments For Restructuring PaymentsForRestructuring	5000000	usd
CY2017Q3	ptn	Upfront Payment Of Less UpfrontPaymentOfLess	500000	usd
CY2017Q3	us-gaap	Payments To Acquire Receivables PaymentsToAcquireReceivables	7500000	usd
	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	547803	usd
CY2024Q1	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	0	usd
	us-gaap	Proceeds From Fees Received ProceedsFromFeesReceived	16434	usd
CY2024Q1	ptn	Equity Expenses Proceeds EquityExpensesProceeds	0	usd
CY2024Q1	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	8236002	usd
CY2023Q2	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	2808598	usd
CY2023Q2	ptn	Cash Equivalents Treasury Bill At Carrying Value CashEquivalentsTreasuryBillAtCarryingValue	2980620	usd
CY2023Q2	ptn	Marketable Securities Treasury Bill At Carrying Value MarketableSecuritiesTreasuryBillAtCarryingValue	2992890	usd
CY2023Q2	ptn	Carrying Value During The Year CarryingValueDuringTheYear	8782108	usd
CY2024Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	2280150	usd
CY2023Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	3856800	usd
	us-gaap	Proceeds From Grantors ProceedsFromGrantors	15000000	usd
	ptn	Voting Of Shares Description VotingOfSharesDescription	The holders of Series C Preferred Stock were entitled to 20,000 votes per share
CY2024Q1	us-gaap	Cash Available For Distributions CashAvailableForDistributions	100	usd
CY2024Q1	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	the Company issued to the investors in the January 2024 RD Offering unregistered warrants (the “January 2024 Private Warrants”) to purchase up to 1,831,503 shares of the Company’s common stock (the “January 2024 Private Warrant Shares”) in a concurrent private placement (the “Private Offering” and together with the January 2024 RD Offering, the “January 2024 Offering”). The shares of common stock and accompanying January 2024 Private Warrants were offered at a combined offering price of $5.46
CY2024Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.46
CY2024Q1	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	6.82
	ptn	Gross Proceeds GrossProceeds	10000006000000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	9224056	usd
CY2023Q4	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	(i) 1,325,000 shares of common stock (the “October 2023 Shares”), of the Company and (ii) pre-funded warrants (the “October 2023 Pre-Funded Warrants”) to purchase up to 1,033,491 shares of the Company’s common stock (the “October 2023 Pre-Funded Warrant Shares”). Pursuant to the October 2023 Purchase Agreement the Company also issued unregistered warrants (the “October 2023 Private Warrants”) to purchase up to 2,358,491 shares of the Company’s common stock (the “October 2023 Private Warrant Shares”) in a concurrent private placement (the “October 2023 Private Offering” and together with the October 2023 RD Offering, the “October 2023 Offering”). The October 2023 Shares and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.12. The October 2023 Pre-Funded Warrants and accompanying October 2023 Private Warrants were offered at a combined offering price of $2.1199
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.12
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2023	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	1033491	shares
CY2023Q4	us-gaap	Costs And Expenses CostsAndExpenses	4573948	usd
CY2022Q4	ptn	Description Of Securities Purchase Agreement DescriptionOfSecuritiesPurchaseAgreement	(i) 1,020,000 shares of the Company’s common stock, (ii) prefunded warrants (the “October 2022 Pre-Funded Warrants”) to purchase up to 798,182 shares of the Company’s common stock, and (iii) common stock warrants (the “October 2022 Common Warrants”) to purchase up to 1,818,182 shares of the Company’s common stock. Each share of common stock was offered with one accompanying October 2022 Common Warrant with a combined offering price of $5.50. Each October 2022 Pre-Funded Warrant was offered with one accompanying October 2022 Common Warrant with a combined offering price of $5.4999
CY2022Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.83
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2022Q4	ptn	Warrant To Purchase Common Stock WarrantToPurchaseCommonStock	798182	shares
CY2022Q4	us-gaap	Costs And Expenses CostsAndExpenses	9109117	usd
	ptn	Description Of Commission DescriptionOfCommission	The Company pays Canaccord 3.0% of the gross proceeds as a commission
CY2024Q1	us-gaap	Proceeds From Other Equity ProceedsFromOtherEquity	0	usd
	ptn	Equity Gross Proceeds Shares EquityGrossProceedsShares	217027	shares
	ptn	Equity Expenses Proceeds EquityExpensesProceeds	0	usd
CY2024Q1	ptn	Equity Net Proceeds Proceeds EquityNetProceedsProceeds	0	usd
	ptn	Equity Net Proceeds Shares EquityNetProceedsShares	217027	shares
	ptn	Equity Net Proceeds Proceeds EquityNetProceedsProceeds	531369	usd
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y10M2D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.8235	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0416	pure
CY2024Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	205176	usd
	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	615716	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberBeginningBalance	1550600	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceBeginningBalance	8.27
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P8Y4M24D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	0
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberEndingBalance	1550600	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceEndingBalance	8.27
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y7M6D
	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding And Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValue	0	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumberEndingBalance	561688	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Option Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionExercisableWeightedAverageExercisePrice	14.18
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M18D
	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Outstanding And Outstanding Aggregate Intrinsic Value Expected ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsOutstandingAndOutstandingAggregateIntrinsicValueExpected	0	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumberEndingBalance	988912	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedExercisePrice	4.91
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y8M12D
	ptn	Share Based Compensation Arrangement By Shares Based Payment Award Options Vested And Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementBySharesBasedPaymentAwardOptionsVestedAndOutstandingAggregateIntrinsicValue	0	usd
CY2024Q1	ptn	Unvested Performance Based Stock Options Granted To Executive Officers And Other Employees UnvestedPerformanceBasedStockOptionsGrantedToExecutiveOfficersAndOtherEmployees	318813	shares
CY2024Q1	ptn	Unvested Performance Based Stock Options Granted UnvestedPerformanceBasedStockOptionsGranted	57999	shares
CY2020Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	87303	usd
CY2021Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	95167	usd
CY2022Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	60566	usd
CY2023Q2	ptn	Unvested Performances Based Restricted Stock Unit UnvestedPerformancesBasedRestrictedStockUnit	238838	usd
CY2024Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	185019	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	555057	usd
CY2023Q1	us-gaap	Restricted Stock Expense RestrictedStockExpense	202512	usd
	us-gaap	Restricted Stock Expense RestrictedStockExpense	612132	usd
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Beginning Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityBeginningBalance	987521	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	2302	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations	18000	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Vested ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsVested	-98372	shares
	ptn	Share Based Compensation Arrangement By Share Based Payment Award Non Option Ending Balance ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEndingBalance	868847	shares
CY2024Q1	ptn	Share Based Compensation Arrangement By Share Based Payment Award Options Veste Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVesteOutstandingNumber	279700	shares
	ptn	Sale Value Of The Tax Benefits To Unaffiliated SaleValueOfTheTaxBenefitsToUnaffiliated	0.80	pure
CY2022Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4674999	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001654954-24-006292-index-headers.html	Edgar Link	pending
0001654954-24-006292-index.html	Edgar Link	pending
0001654954-24-006292.txt	Edgar Link	pending
0001654954-24-006292-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
ptn-20240331.xsd	Edgar Link	pending
ptn_10q.htm	Edgar Link	pending
ptn_10qimg19.jpg	Edgar Link	pending
ptn_10qimg20.jpg	Edgar Link	pending
ptn_ex311.htm	Edgar Link	pending
ptn_ex312.htm	Edgar Link	pending
ptn_ex321.htm	Edgar Link	pending
ptn_ex322.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
ptn-20240331_cal.xml	Edgar Link	unprocessable
ptn-20240331_def.xml	Edgar Link	unprocessable
ptn-20240331_lab.xml	Edgar Link	unprocessable
ptn-20240331_pre.xml	Edgar Link	unprocessable
ptn_10q_htm.xml	Edgar Link	completed
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q2 Form 10-Q Financial Statement

#000165495424006292 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN PALATIN TECHNOLOGIES INC Stock $ptn

2024 Q2 Form 10-Q Financial Statement

#000165495424006292 Filed on May 15, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PTN
PALATIN TECHNOLOGIES INC Stock $ptn